SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Infinity Pharmaceuticals, Inc. (INFI) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 26/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — INFI
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.28
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.48
Book Value / Share$0.00
Revenue / Share$0.03
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-2.64 |
$0.00 |
$-126.78M |
- |
| 2014 |
$-0.36 |
$165M |
$-17.42M |
-10.6% |
| 2015 |
$-2.62 |
$109.07M |
$-128.38M |
-117.7% |
| 2016 |
$-0.61 |
$18.72M |
$-30.1M |
-160.8% |
| 2017 |
$-0.83 |
$6M |
$-41.83M |
-697.2% |
| 2018 |
$-0.20 |
$22.15M |
$-11.25M |
-50.8% |
| 2019 |
$-0.83 |
$3.05M |
$-47.06M |
-1543.4% |
| 2020 |
$-0.72 |
$1.72M |
$-42.94M |
-2497.8% |
| 2021 |
$-0.53 |
$1.86M |
$-45.44M |
-2445.7% |
| 2022 |
$-0.48 |
$2.59M |
$-43.26M |
-1668.2% |
